BR112017008291A2 - oligonucleotídeos para edição de dna genômico - Google Patents

oligonucleotídeos para edição de dna genômico

Info

Publication number
BR112017008291A2
BR112017008291A2 BR112017008291A BR112017008291A BR112017008291A2 BR 112017008291 A2 BR112017008291 A2 BR 112017008291A2 BR 112017008291 A BR112017008291 A BR 112017008291A BR 112017008291 A BR112017008291 A BR 112017008291A BR 112017008291 A2 BR112017008291 A2 BR 112017008291A2
Authority
BR
Brazil
Prior art keywords
dna sequence
chromosomal dna
oligonucleotides
genomic dna
cell
Prior art date
Application number
BR112017008291A
Other languages
English (en)
Inventor
Swildens Jim
Holkers Maarten
Original Assignee
Proqr Therapeutics Ii Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proqr Therapeutics Ii Bv filed Critical Proqr Therapeutics Ii Bv
Publication of BR112017008291A2 publication Critical patent/BR112017008291A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

um método para fazer uma alteração em uma sequência de dna cromossomal endógena de uma célula de mamífero, compreendendo as etapas de: (i) introduzir na referida célula um oligonucleotídeo possuindo uma sequência que é complementar à sequência de dna cromossomal e que inclui a alteração; (ii) permitir tempo suficiente para a célula incorporar a alteração na sequência de dna cromossomal endógena através de vias modificadoras de ácidos nucleicos endógenos; e (iii) identificar a presença da alteração na sequência de dna cromossomal. a invenção é particularmente útil para corrigir mutações no gene cftr.
BR112017008291A 2014-10-23 2015-10-23 oligonucleotídeos para edição de dna genômico BR112017008291A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1418892.4A GB201418892D0 (en) 2014-10-23 2014-10-23 DNA editing
PCT/EP2015/074675 WO2016062886A1 (en) 2014-10-23 2015-10-23 Oligonucleotides for genomic dna editing

Publications (1)

Publication Number Publication Date
BR112017008291A2 true BR112017008291A2 (pt) 2018-05-02

Family

ID=52103302

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017008291A BR112017008291A2 (pt) 2014-10-23 2015-10-23 oligonucleotídeos para edição de dna genômico

Country Status (10)

Country Link
US (1) US20170327821A1 (pt)
EP (1) EP3209779A1 (pt)
KR (1) KR20170070061A (pt)
CN (1) CN107208090A (pt)
AU (1) AU2015334835A1 (pt)
BR (1) BR112017008291A2 (pt)
CA (1) CA2963323A1 (pt)
GB (1) GB201418892D0 (pt)
IL (1) IL251701A0 (pt)
WO (1) WO2016062886A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3219705T3 (da) 2005-12-28 2020-04-14 Vertex Pharma Farmaceutiske sammensætninger af den amorfe form af n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinolin-3-carboxamid
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
US10206877B2 (en) 2014-04-15 2019-02-19 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
RU2711506C2 (ru) 2014-12-17 2020-01-17 ПРОКЬЮЭР ТЕРАПЬЮТИКС II Би.Ви. Редактирование целевой рнк
AU2017281497B2 (en) 2016-06-22 2023-04-06 Proqr Therapeutics Ii B.V. Single-stranded RNA-editing oligonucleotides
PT3507366T (pt) 2016-09-01 2020-11-09 Proqr Therapeutics Ii Bv Oligonucleótidos de cadeia simples quimicamente modificados de edição de rna
US11274300B2 (en) 2017-01-19 2022-03-15 Proqr Therapeutics Ii B.V. Oligonucleotide complexes for use in RNA editing
CN107267516B (zh) * 2017-07-28 2020-09-29 佛山科学技术学院 双sgRNA介导的基因精确修饰方法及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2775346B2 (ja) * 1992-04-03 1998-07-16 アプライド バイオシステムズ，インコーポレイテッド プローブ構成物および方法
US6180408B1 (en) * 1998-08-21 2001-01-30 Washington University Fluorescence polarization in nucleic acid analysis
AUPR221400A0 (en) * 2000-12-20 2001-01-25 Murdoch Childrens Research Institute, The Diagnostic assay
NZ703824A (en) * 2012-07-12 2018-06-29 Proqr Therapeutics Ii Bv Oligonucleotides for making a change in the sequence of a target rna molecule present in a living cell

Also Published As

Publication number Publication date
EP3209779A1 (en) 2017-08-30
IL251701A0 (en) 2017-06-29
AU2015334835A1 (en) 2017-04-27
US20170327821A1 (en) 2017-11-16
KR20170070061A (ko) 2017-06-21
GB201418892D0 (en) 2014-12-10
CN107208090A (zh) 2017-09-26
CA2963323A1 (en) 2016-04-28
WO2016062886A1 (en) 2016-04-28

Similar Documents

Publication Publication Date Title
BR112017008291A2 (pt) oligonucleotídeos para edição de dna genômico
BR112016019267B8 (pt) Método para construir um perfil de dna, biblioteca de ácido nucléico, método para construir uma biblioteca de ácido nucléico, pluralidade de iniciadores e kit
BR112016019940A2 (pt) edição de genoma sem nucleases
BR112017012765A2 (pt) ?métodos para editar uma sequência de nucleotídeos, célula e linhagem de e. coli e método para produzir uma célula de e. coli?
BR112017011510A2 (pt) edição de rna direcionado
MX2022000378A (es) Metodos y composiciones para la modificacion genetica dirigida mediante el uso de arn guia combinados.
BR112018007177A2 (pt) edição de genoma multiplexado
BR112018010681A8 (pt) método para modificar um sítio alvejado, complexo de enzima de modificação de ácido nucleico, e, ácido nucleico.
SG10201903408VA (en) Contiguity preserving transposition
GB2544001A (en) Methods for increasing Cas9-mediated engineering efficiency
BR112017023189A2 (pt) aparelho de efeito de campo e métodos para sequenciar ácidos nucleicos
EP3350732A4 (en) METHOD FOR GENERATING A LIBRARY WITH SEQUENCING OF THE NEXT GENERATION (NGS) FROM A RIBONUCLEIC ACID (RNA) SAMPLE AND COMPOSITIONS FOR IMPLEMENTING THEREOF
BR112016025519A2 (pt) engenharia genética in vivo com vetores de adenovírus
MX2016007541A (es) Moléculas modificadas de ácido nucleico y usos de las mismas.
EP3192900A4 (en) Method for constructing nucleic acid single-stranded cyclic library and reagents thereof
BR112015030491A2 (pt) regulação transcricional guiada por rna
MX2015011435A (es) Amplificación de ácidos nucléicos.
CY1122975T1 (el) Συνθεσεις και μεθοδοι για την αναστολη της εκφρασης του γονιδιου alas1
BR112017011217A2 (pt) impurezas de dna em uma composição compreendendo um vírion parvoviral
EP3222718A4 (en) Method for knock-in of dna into target region of mammalian genome, and cell
DK3242903T3 (da) Sammensætninger til at indføre nukleinsyre i celler
EP3237613A4 (en) Visualizing modified nucleotides and nucleic acid interactions in single cells
EP3455379A4 (en) RIBONUCLEIC ACID (RNA) INTERACTIONS
IL277813A (en) Tm-enhanced double-helix nucleic acid tracer molecules with nucleotides
BR112017006542A2 (pt) mutantes de recombinase

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]